Jensen Quality Growth Equity Strategy, a US-based asset management fund, issued its second-quarter 2026 investor letter detailing portfolio performance and specific holdings. The fund returned 10.94% net of fees during the quarter, trailing the S&P 500 Index’s 15.20% return. Market strength during the period was driven by easing geopolitical tensions, improved financial conditions, sustained consumer spending, and ongoing investment in artificial intelligence infrastructure. However, the fund’s performance was hindered as lower-quality and momentum stocks outperformed the quality-focused approach that anchors the strategy.
Among its holdings, Abbott Laboratories drew particular attention in the fund’s commentary. The healthcare company closed at $103.06 per share on July 24, with a one-month gain of 7.04% but a 52-week loss of 18.43%. The company carries a market capitalization of approximately $179.51 billion. Jensen highlighted that Abbott’s stock declined following the release of first-quarter earnings and subsequent management actions.
The fund attributed Abbott’s underperformance to multiple headwinds. Management reduced full-year guidance to account for dilution stemming from the Exact Sciences acquisition. Additionally, certain business segments, particularly Nutrition and portions of Diagnostics, encountered near-term challenges. Litigation uncertainty related to necrotizing enterocolitis connected to preterm infant formula continued to weigh on investor sentiment regarding the stock. Despite these pressures, the fund noted that Abbott’s Medical Devices and Established Pharma segments delivered strong results with high-single-digit organic growth, with these two areas representing over 62% of first-quarter sales.
As of the first quarter, 73 hedge fund portfolios held Abbott Laboratories, compared to 71 in the preceding quarter. However, Jensen indicated a preference for certain artificial intelligence-focused stocks, which the fund views as offering greater upside potential and lower downside risk compared to Abbott’s current risk-reward profile.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI